Naloxone Protects against Lipopolysaccharide-Induced Neuroinflammation and Microglial Activation via Inhibiting ATP-Sensitive Potassium Channel

Comput Math Methods Med. 2021 Jul 29:2021:7731528. doi: 10.1155/2021/7731528. eCollection 2021.

Abstract

Aim: The aim of this study was to evaluate the anti-inflammatory effects and underlying mechanism of naloxone on lipopolysaccharide- (LPS-) induced neuronal inflammation and microglial activation.

Methods: LPS-treated microglial BV-2 cells and mice were used to investigate the anti-inflammatory effects of naloxone.

Results: The results showed that naloxone dose-dependently promoted cell proliferation in LPS-induced BV-2 cells, downregulated the expression of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) and proinflammatory enzymes iNOS and COX-2 as well as the expression of free radical molecule NO, and reduced the expression of Iba-1-positive microglia in LPS-stimulated BV-2 cells and mouse brain. Moreover, naloxone improved LPS-induced behavior degeneration in mice. Mechanically, naloxone inhibited LPS-induced activation in the ATP-sensitive potassium (KATP) channel. However, the presence of glibenclamide (Glib), an antagonist of KATP channel, ameliorated the suppressive effects of naloxone on inflammation and microglial activation.

Conclusion: Naloxone prevented LPS-induced neuroinflammation and microglial activation partially through the KATP channel. These findings might highlight the potential of naloxone in neuroinflammation therapy.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Behavior, Animal / drug effects
  • Cell Line
  • Cell Proliferation / drug effects
  • Computational Biology
  • Disease Models, Animal
  • Inflammation / chemically induced
  • Inflammation / metabolism
  • Inflammation / prevention & control*
  • KATP Channels / antagonists & inhibitors*
  • Lipopolysaccharides / toxicity
  • Mice
  • Mice, Inbred BALB C
  • Microglia / drug effects*
  • Microglia / metabolism
  • Microglia / pathology
  • Naloxone / pharmacology*
  • Narcotic Antagonists / pharmacology
  • Neurodegenerative Diseases / chemically induced
  • Neurodegenerative Diseases / metabolism
  • Neurodegenerative Diseases / prevention & control

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • KATP Channels
  • Lipopolysaccharides
  • Narcotic Antagonists
  • Naloxone